Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Damien McDevitt has been named CEO of rare disease pharma company Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals. Previously, McDevitt was chief business officer for Ionis.
Athersys has announced the appointment of Maia Hansen to the role of senior vice president of operations and supply chain. Hansen most recently served as senior partner of global management consulting firm McKinsey & Co.
Beam Therapeutics appointed Christine Swenson to the position of senior vice president of regulatory affairs. Swenson was most recently senior vice president of global regulatory affairs at Moderna.
Bristol Myers Squibb
Bristol Myers Squibb has named Elizabeth Mily executive vice president of strategy and business development. Prior to this appointment, Mily was the managing director and chair of life sciences at Barclays.
Chembio Diagnostic Systems
Chembio Diagnostic Systems has appointed Richard Eberly as CEO. Previously, Eberly was a managing director at Solid Rock Principled Capital, a healthcare private equity firm.
Jacob Lalezari has been named interim chief medical officer of CytoDyn. Lalezari will continue to serve as CEO and director of Quest Clinical Research.
Kathryn Beiser will assume the role of vice president of global communications at Eli Lilly. Most recently, Beiser served as senior vice president and chief communications officer at Kaiser Permanente.
Kathleen Wolf has joined data collection and clinical research monitoring company Emmes as the company’s new vice president of clinical operations. Previously, Wolf was senior director and head of clinical operations at AstraZeneca’s MedImmune.
Jeffery Kutok has joined Epizyme as its chief scientific officer. Most recently, Kutok served as chief scientific officer of Infinity Pharmaceuticals.
Paul Wren has been named chief scientific officer of ESCAPE Bio, a biopharmaceutical company focused on neurodegenerative diseases. Prior to joining ESCAPE, Wren was senior director of neuroscience discovery at GlaxoSmithKline.
EVERSANA has named Ed Cox the company’s new executive vice president or strategic alliances and global head of digital medicine practice. Cox was most recently CEO of Dthera Sciences.
Julie O’Donnell has been appointed to the role of vice president and global head of digital at Evoke Kyne. Prior to this appointment, O’Donnell was senior director and headed the digital team at pharmaceutical company Lundbeck.
Biotech company Freeline has brought on Julie Krop as the firm’s newest chief medical officer. Krop comes to Freeline after serving as chief medical officer of AMAG Pharmaceuticals.
Fusion Pharmaceuticals has found its new chief medical officer in James O’Leary. Prior to joining Fusion Pharmaceuticals, O’Leary was an independent oncology consultant and vice president/chief medical officer of ImmunoGen.
Gene therapy company Genprex appointed Catherine Vaczy to the role of executive vice president and chief strategy officer. Previously, Vaczy was principal at the Finial Group, where she provided strategic advisory services to early stage biotech firms. Michael Redman has also accepted the role of executive vice president and chief operating officer at Genprex. Prior to this position, Redman was president and CEO of Oncolix.
Christina Brattström has been recruited as Idogen’s newest chief medical officer. Most recently, Brattström was medical director at Bayer HealthCare.
Douglas Onsi has replaced Chris Mirabelli as president and CEO of Leap Therapeutics. Onsi will continue to maintain his role as Leap’s chief financial officer. Cynthia Sirard, Leap’s vice president of clinical R&D, has been promoted to the role of chief medical officer. Additionally, Mark O’Mahony, vice president of manufacturing at Leap, has been promoted to chief manufacturing officer.
Morphic Therapeutic has appointed Peter Linde to the role of chief medical officer. Prior to this appointment, Linde was vice president of medical research at Acceleron.
Dominic Smethurst will serve as the interim chief medical officer for Nordic Nanovector, replacing Lisa Rojkjaer. Smethurst previously held the role of group medical director of Tusk Therapeutics.
Jon Burrows has been named CEO of Oxford BioDynamics, joining the UK-based company after serving as executive vice president of Oncology Partners, a consulting and clinical advisory firm.
Thierry Bernard has been named the permanent CEO of Qiagen following the departure of Peer Schatz. Bernard has been with Qiagen since 2015 in the role of senior executive vice president of molecular diagnostics business.
Ra Medical Systems
Will McGuire has been appointed CEO of Ra Medical Systems. Most recently, McGuire was president and CEO of Second Sight Medical Products.
Shafique Virani has been named chief corporate development officer of AI biotech Recursion. Most recently, Virani was CEO of Navire Pharma and CoA Therapeutics.
Relmada Therapeutics has announced that Judy Caron will join the company as its newest vice president of drug development. Caron was most recently chief operating officer and head of clinical development for Neurana Pharmaceuticals, a company she cofounded in 2012.
David Boulware, infectious disease physician-scientist and professor of medicine in the division of infectious diseases and international medicine at the University of Minnesota, has been appointed to the role of scientific advisor for infectious diseases at Revive Therapeutics. Currently, Boulware is the principal investigator for a COVID-19 trial studying the use of prophylaxis hydroxychloroquine after COVID-19 exposure.
RubrYc Therapeutics has appointed Ramesh Baliga to the role of chief scientific officer. Baliga joins the company from IGM Biosciences, where he served as the vice president of discovery biology.
Robert Pierce has been hired by Sensei Biotherapeutics to assume the role of chief scientific officer. Most recently, Pierce was scientific director of the immunopathology lab at the Fred Hutchinson Cancer Research Center.
Thrive Earlier Detection
Matt Franklin has been named chief commercial officer of Thrive Earlier Detection. Franklin was tapped from molecular diagnostics company ArcherDx, where he served as chief business officer.
Jeff Bova, previous senior vice president of commercial of UroGen Pharma, has been promoted to the role of chief commercial officer. UroGen has promoted Marina Konorty from the role of senior vice president of research and development and head of Israeli operations to executive vice president of research and development and technical operations. James Ottinger, UroGen’s senior vice president of regulatory affairs, has also been promoted to the position of executive vice president of regulatory affairs and quality. UroGen also announced the promotion of Elyse Seltzer, the company’s senior vice president of clinical development, to the role of chief development officer.
Jim Robinson has been tapped from his position as chief operating officer of Paragon Biosciences to take on the role of CEO at Urovant Sciences.
Viracta Therapeutics has appointed Lisa Rojkjaer to the role of chief medical officer. Rojkjaer was most recently chief medical officer of Nordic Nanovector, prior to joining Viracta.